Understanding chronic migraine
Chronic migraine is defined as experiencing 15 or more headache days per month, with at least 8 of those days having migraine features. It is a debilitating neurological condition that affects roughly 1 million people in the UK. The impact goes far beyond headache pain, often including nausea, sensitivity to light and sound, and difficulty concentrating.
For many people, migraine is episodic and manageable. But when it becomes chronic, it can dominate daily life, affecting work, relationships, and overall wellbeing. The unpredictability of attacks adds another layer of difficulty, making it hard to plan or commit to activities with confidence.
Preventive medications exist, but they often come with significant side effects, and many people find them only partially effective. This creates a real need for additional approaches that can reduce migraine frequency without adding to the burden of side effects.
How tVNS helps
Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive way to stimulate the vagus nerve through the skin of the ear. A small clip-style electrode attaches to the outer ear, targeting the auricular branch of the vagus nerve. The device delivers gentle electrical pulses that you might feel as a mild tingling sensation.
These electrical signals travel along the vagus nerve to the brainstem, where they influence pathways involved in pain processing. Specifically, tVNS modulates activity in the trigeminal nerve system, which is the primary pain pathway involved in migraine. It also affects brainstem centres that regulate how pain signals are amplified or dampened before they reach conscious awareness.
In simpler terms, tVNS appears to help turn down the volume on the overactive pain signalling that characterises chronic migraine. Rather than blocking pain after it has started, regular use aims to reduce the likelihood and severity of migraine attacks over time.
The evidence
The tVNS device holds Class IIa certification under EU Medical Device Regulation for chronic migraines, meaning it has met the regulatory standard for safety and clinical performance. Cervical (neck-based) vagus nerve stimulation devices, such as the gammaCore system, also hold FDA clearance for both acute and preventive treatment of migraine and cluster headaches.
The clinical data is encouraging. Studies have demonstrated a 50% reduction in migraine days at 12 weeks of treatment. In the PREVA study, which focused on cluster headaches (a related condition), patients using transcutaneous cervical VNS as an adjunct to standard care experienced 5.9 fewer cluster headache attacks per week compared to standard care alone.
These numbers represent meaningful improvements in daily life. Halving the number of migraine days in a month can mean the difference between being unable to work reliably and having a more predictable routine.
It is important to be straightforward about what we know and what we are still learning. The evidence base for tVNS in migraine continues to grow, and results do vary between individuals. Not everyone will achieve a 50% reduction, and some people may see more modest improvements. What the research consistently shows is that tVNS offers a credible, evidence-based option for migraine management with a favourable side effect profile.
What treatment looks like
tVNS is designed for daily home use, making it a practical addition to your existing migraine management plan. The device clips onto the outer ear, and a typical treatment session lasts between one and four hours per day. Many people build it into their routine while reading, watching television, or resting.
Your clinician will set the stimulation parameters, including the intensity, pulse width, and frequency. These are tailored to you and adjusted over time based on your response. A companion app allows you to track your sessions and migraine patterns, which gives both you and your clinical team useful data for managing your treatment.
It is important to understand that tVNS is not a replacement for your current migraine management. It works alongside your existing treatments, whether those include medication, lifestyle modifications, or other approaches. The aim is to provide an additional tool that can help reduce your overall migraine burden.
Is this right for me?
Whether tVNS is appropriate for you depends on your individual circumstances, and that assessment needs to be made with a qualified clinician.
tVNS may be worth considering if you experience chronic migraine and have found that preventive medications are not providing adequate control, or if side effects from medication are affecting your quality of life. It may also be relevant if you are looking for a non-pharmacological approach to complement your current management.
Not everyone is suitable for tVNS. There are contraindications that your clinician will check for, including implanted cardiac devices such as pacemakers or defibrillators, and certain other medical conditions. A thorough clinical assessment is always the first step.
It is also honest to say that response to tVNS varies. Some people experience a significant reduction in migraine frequency, while others see more modest improvements. Migraine is a complex neurological condition, and no single treatment works equally well for everyone. What the evidence does tell us is that for those who respond, tVNS can make a meaningful difference to daily life.
Next steps
If you would like to find out whether tVNS could be part of your migraine management, we are here to help. Contact us to arrange a clinical assessment where we can discuss your situation, answer your questions, and help you make an informed decision about whether this approach is right for you.